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Background. This study was conducted to investigate the incidence of, and factors associated with, myoclonus-like abnormal
movements of Japanese infants following treatment with midazolam in a neonatal intensive care unit (NICU). Methods.W e
retrospectively investigated abnormalmovements and associated riskfactors inJapanese infants (less than1 year old) who received
continuous intravenous midazolam treatment in the NICU of the Neonatal Medical Center, Kumamoto City Hospital, Japan,
between April 2007 and March 2009. Results. The study included 94 infants who received 119 sessions of midazolam treatment
in total. Nine infants (9.6%) developed abnormal movements attributable to midazolam. These nine patients had a signiﬁcantly
lower gestational age at birth, a signiﬁcantly lower number of weeks after conception at the start of midazolam treatment, and
signiﬁcantlylowerbodyweightcomparedwithpatientsfreeofabnormalmovements.Logisticregressionanalysisrevealedneonatal
asphyxia as a factor associated with an elevated risk of abnormal movements (P = 0.03). Conclusion. The incidence of abnormal
movements after midazolam treatment was about 9.6% among the Japanese NICU infants. This result suggests that neonatal
asphyxia may be involved in the onset of abnormal movements in infants treated with midazolam.
1.Introduction
Infantsinaneonatalintensivecareunit(NICU)oftenreceive
repeated painful and/or stressful manipulations, tests, and
treatments [1]. Neonates are sensitive to pain [2, 3], and it
has been reported that prolonged exposure to pain or stress
can adversely aﬀect the mental and physical development of
sick children [4–8]. Therefore, administration of safe and
appropriate analgesic and sedative treatments is important
for these patients.
Midazolam is a short-acting water-soluble benzodiaze-
pine derivative and is now approved only in adults in Japan
as a means of “sedation during mechanical ventilation.”
Meanwhile, this sedative is already used as a nonapproved
treatment in neonates and infants [9, 10]. Thus, eﬀorts are
being made to expand the indications for midazolam to be
administered to children.
An adverse reaction, myoclonus-like abnormal move-
ments, has been reported after midazolam administration
in neonates, particularly premature and low-birth-weight
infants [11]. Magny et al. [12] reported abnormal move-
ments in six (5.9%) of 102 neonates managed at the Antoine
Beclere Hospital NICU (Clamart, France). In a prospective
study at the Paediatric Intensive Care Unit of Alder Hey
Children’s Hospital (Liverpool, UK), Hughes et al. [13]
observedabnormalmovementsinfour(7.5%)of53critically2 ISRN Pharmacology
ill infants/children at the Paediatric Intensive Care Unit of
Alder Hey Children’s Hospital (Liverpool, UK). To date,
however, very few reports have been published concerning
the risk factors associated with development of abnormal
movements after administration of midazolam.
The present study was conducted to investigate risk
factors involved in the development of abnormal movements
in patients managed at the NICU of the Neonatal Medical
Center, Kumamoto City Hospital, Japan, focusing on abnor-
mal movements associated with midazolam.
2. Methods
We performed a retrospective analysis of medical records
of Japanese infants aged less than 1 year who received con-
tinuous midazolam treatment at the NICU of the Neonatal
Medical Center, Kumamoto City Hospital, Japan, between
April 2007 and March 2009. The study was approved by the
Ethics Committee of Kumamoto City Hospital (no. 169).
The cases included those infants in whom the physician
noted abnormal movements after the start of midazolam
treatment and which disappeared after discontinuation of
midazolam. The following data were collected: gender;
gestational age at birth; birth weight; Apgar score at 1 and
5 minutes; age at the start of midazolam treatment; number
of weeks after conception; body weight; dose level at the
start of treatment; presence/absence of neonatal asphyxia,
intracranial bleeding, neonatal seizure, hypocalcemia, vita-
min K deﬁciency, hydrocephalus, apnea, and hypoxia.
Theinfantswereclassiﬁedintotwogroups;theabnormal
movement (+) group and the abnormal movement (−)
group. The abnormal movement (+) group included infants
who developed abnormal movements on administration of
midazolam. The abnormal movement (−) group included
infantsfreeofabnormalmovementsonadministrationofthe
drug.
DataofthetwogroupswerecomparedusingtheStudents
t-test (parametric continuous variables), the Mann-Whitney
U test (nonparametric continuous variables), or Fisher’s
exact test (categorical variables). Logistic regression analysis
was used to identify factors associated with the appearance
of abnormal movements. Statistical analysis was performed
using PRISM (version 3.0, GraphPad Software, Inc., San
Diego, CA, USA) and Microsoft Excel. A two-tailed P-value
< 0.05 was considered to indicate statistical signiﬁcance.
3. Results
Midazolam was continuously administered to 94 patients
(119 sessions). Abnormal movements were identiﬁed in nine
patients, an incidence of 9.6% in the infants less than 1
year of age admitted to the NICU. Abnormal movements
were never observed after discontinuation of midazolam
in patients included in abnormal movement (+) group.
Comparison of the background variables between the abnor-
mal movement (+) group and the abnormal movement
(−) group is shown in Table 1. There was no signiﬁcant
diﬀerence in terms of gender, Apgar score at 1 or 5 minutes,
birth weight, age at the start of midazolam treatment, or
dose at the start of midazolam treatment between the two
groups. The gestational age at birth, number of weeks
after conception at the start of midazolam treatment, and
body weight at intervention were signiﬁcantly lower in the
abnormal movement (+) group.
The individual background variables of the nine patients
with abnormal movements are shown in Table 2.T h et i m e
from the start of midazolam treatment to appearance of
abnormal movements was 0.1–42h (mean, 7.2h). Of these
nine patients, eight had neonatal asphyxia and three were
diagnosed as having intracranial bleeding.
The results of multiple logistic regression analysis are
shown in Table 3. A diagnosis of neonatal asphyxia was iden-
tiﬁed as a factor associated with increased risk of developing
abnormal movements after midazolam administration (P =
0.03).
4. Discussion
This retrospective study showed that the incidence of abnor-
mal movements following treatment with midazolam was
9.6% among the Japanese infants aged less than 1 year
managed at the NICU of the Neonatal Medical Center,
Kumamoto City Hospital. Furthermore, multiple logistic
regression analysis suggested neonatal asphyxia as a factor
associated with increased the risk of developing abnormal
movements. In the present study, the gestational age at
birth, the number of weeks after conception at the start of
midazolam treatment, and the body weight were lower in
the abnormal movement (+) group than in the abnormal
movement (−) group, suggesting that the infants with
abnormal movements were preterm births than the infants
who did not develop abnormal movements. Magny et al.
[12] reported that the gestational age at birth was 27–34
weeks and the birth weight was 970–2060g in six children
withabnormalmovements,andWaismanetal.[14]reported
that the gestational age at birth was 24–26 weeks and the
birth weight was 617 (170)g (mean (standard deviation)) in
three children with abnormal movements. Our results were
consistent with these previous ﬁndings and suggest that the
abnormal movements were associated with prematurity, that
is, gestational age at birth and birth weight.
In the present study, logistic regression analysis revealed
neonatal asphyxia as a factor signiﬁcantly associated with
midazolam-induced abnormal movements, whereas none
of the indicators of prematurity (gestational age at birth,
number of weeks after conception at the start of midazolam
treatment, age, birth weight, etc.) was found to be signif-
icantly associated with the appearance of abnormal move-
ments. It, therefore, seems probable that these indicators
of prematurity are confounding factors related to neonatal
asphyxia, while neonatal asphyxia, a condition associated
with prematurity, is a risk factor for midazolam-induced
abnormal movements in infants.
In this study, the midazolam dosing period was much
shorter in the abnormal movements (+) group than in the
abnormal movements (−) group, indicating that abnormalISRN Pharmacology 3
Table 1: Characteristics of the infants.
Abnormal movement (+) Abnormal movement (−) P-value
Case (male/female) 9 (4/5) 110 (67/43) 0.34
Gestational age (weeks)a 30.1 (5.8) 34.3 (5.8) 0.04
Apgar score 1b 3.5 (1–8) 7 (0–10) 0.07
Apgar score 5b 7 (5–9) 8 (1–10) 0.68
Birth weight (g)a 1492 (1045) 2109 (1074) 0.10
Postnatal age when midazolam administration
was started (days)a 17.2 (26.8) 41.9 (59.3) 0.25
Postconceptional age when midazolam
administration was started (weeks)a 32.5 (5.0) 40.1 (9.1) 0.01
Body weight when midazolam administration was
started (g)a 1531 (961) 2592 (1331) 0.02
Dose of midazolam (mg·kg−1·h−1)a
0.14 (0.06) 0.21 (0.10) 0.05
Duration of midazolam administration (h)a 7.2 (13.3) 162.3 (234.2) <0.0001
aData are expressed as mean (standard deviation).
bData are expressed as median (range).
Table 2: Characteristics of infants in the abnormal movement (+) group.
No Sex
At birth At the start of midazolam treatment Duration of midazolam
administration (h)
Birth
asphyxia
Intracranial
hemorrhage
GA
(weeks)
Apgar
score
1/5min
Weight
(g)
PNA
(days)
PCA
(weeks)
Weight
(g)
Dose
(mg/kg/h)
(1) F 27.0 5/7 862 0 27.0 862 0.17 6.0 +
(2) M 25.1 4/5 757 16 27.4 826 0.09 42.0 ++
(3) M 25.3 1/5 814 20 28.2 814 0.09 6.0 ++ ++
(4) M 30.4 3/7 1232 1 30.6 1232 0.08 5.8 ++ +++
(5) F 30.7 −/− 1405 1 30.9 1331 0.23 1.7 + ++
(6) M 29.0 2/7 1451 32 33.6 1524 0.10 0.1 ++
(7) F 24.4 3/7 559 82 36.1 1108 0.20 1.5 ++
(8) F 38.0 7/8 2580 3 38.4 2306 0.21 0.7 +
(9) F 40.7 8/9 3773 0 40.7 3773 0.13 1.0
GA, gestational age; PNA, postnatal age; PCA, postconceptional age.
movements occurred within a few hours after the start of
midazolamtreatment,resultinginwithdrawalofmidazolam.
This indicates that close monitoring of adverse reactions to
midazolam is essential in the few hours after administration.
However, one patient developed abnormal movements 42h
after the start of midazolam treatment. This case suggests
that it is necessary to be aware of the possibility that
abnormal movements can appear even several days after the
start of midazolam treatment. Further studies are required
regarding the time of appearance of abnormal movements
after the start of midazolam treatment.
The present study has the following limitations. First, the
cases included those infants in whom the physician noted
abnormal movements after the start of midazolam treatment
and which disappeared after discontinuation of midazolam
in this retrospective study. Although the infants in our
neonatal intensive care unit have been observed by physician
and trained medical staﬀs, no deﬁnitive methods of deter-
mination of the abnormal movements (such as, frequency
and duration of observation, and onset time the abnormal
movements) have been deﬁned. Second, the development
of abnormal movements was investigated retrospectively,
and patients were rated as having abnormal movements if
the following criteria were met: (1) medication was sus-
pended at the discretion of the attending physician because
of detection of abnormal movements and (2) abnormal
movements disappeared after discontinuation of the drug.
In addition, discrimination between abnormal movements
associatedwithmidazolamandunrelatedconvulsiveseizures
is extremely diﬃcult, because there is no distinction in the
clinical signs nor a deﬁnitive diﬀerential diagnosis for the
two entities. Therefore, the incidence of abnormal move-
ments induced by midazolam may not have been accurately
determined. Besides, the incidence of “midazolam-unrelated4 ISRN Pharmacology
Table 3: Logistic regression analysis of factors associated with the appearance of abnormal movements.
Number Odds ratio (95% CI) P-value
Sex
Female 38 1 (Reference) 0.12
Male 56 0.10 (0.01–1.82)
Gestational age (weeks) 94 0.50 (0.21–1.20) 0.12
Apgar score 1 94 1.23 (0.37–4.11) 0.73
Apgar score 5 94 3.20 (0.88–12.33) 0.08
Birth weight (g) 94 1.00 (0.99–1.00) 0.46
Postnatal age (days) 94 0.94 (0.86–1.04) 0.24
Postconceptional age (weeks) 94 1.00 (0.97–1.03) 0.98
Body weight (g) 94 1.00 (0.99–1.00) 0.65
Dose of midazolam (mg/kg/h) 94 <0.001 (<0.001–>999.999) 0.26
Birth asphyxia 0.03
No 64 1 (Reference)
Yes 30 108.04 (1.50–>999.999)
Intracranial hemorrhage 0.27
No 86 1 (Reference)
Yes 8 5.41 (0.27–109.63)
Neonatal seizure 0.32
No 87 1 (Reference)
Yes 7 10.99 (0.09–>999.999)
Hypocalcemia 0.88
No 68 1 (Reference)
Yes 26 0.83 (0.077–8.98)
Vitamin K deﬁciency 0.78
No 81 1 (Reference)
Yes 13 0.62 (0.02–17.04)
Hydrocephalus 0.99
No 91 1 (Reference)
Yes 3 <0.001 (<0.001–>999.999)
Apnea 0.65
No 85 1 (Reference)
Yes 9 0.37 (0.005–28.49)
Hypoxia 0.99
No 91 1 (Reference)
Yes 3 <0.001 (<0.001–>999.999)
CI, conﬁdence interval.
abnormal movements” in Japanese infants in our neonatal
intensive care unit cannot be exactly determined. It may be
desirable to objectively assess the appearance of abnormal
movements by using electroencephalography, and so forth.
Further studies could analyze the relationship between
the appearance of abnormal movements and the phar-
macokinetics of midazolam. Some investigators reported
that the half-life of midazolam was extended in preterm
newborns and low-birth-weight newborns, accompanied by
reduced drug clearance [15–17]. In view of these reports,
we cannot rule out the possibility that metabolism and
e x c r e t i o no fm i d a z o l a ma r ed e l a y e di np r e t e r ma n dl o w -
birth-weight newborns, resulting in high plasma levels. In
this study, we did not survey the concurrent medications
which can modulate the pharmacokinetics of midazolam
and can solely be a risk factor of abnormal movements. It
would be desirable to conduct a prospective study, taking
these factors into account, to further investigate midazolam-
associated abnormal movements in Japanese infants man-
aged at NICUs, and also to investigate whether there is an
association of intracranial bleeding (a proposed risk factor)
with abnormal movements.
5. Conclusion
The present study provided data on the incidence of mid-
azolam-induced abnormal movements among the JapaneseISRN Pharmacology 5
infants managed at the NICU and suggested that neonatal
asphyxia was a risk factor for such abnormal movements.
The results indicate that, when treating highly preterm
neonates, particularly those diagnosed as having neonatal
asphyxia, careful use and monitoring of midazolam is
essential.
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